Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Hepatology"
DOI: 10.1002/hep.32023
Abstract: Lenvatinib is an effective drug in advanced HCC. Its combination with the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in… read more here.
Keywords: death protein; immunomodulatory effects; programmed cell; cell death ... See more keywords